Global Influenza Virus B Infection Drug Market Valued at $0.99 billion in 2025, Set to Grow at a 2.4% CAGR

Influenza Virus B Infection Drug market was valued at $0.99 billion in 2025 and is projected to reach $1.2 billion by 2035, growing at a CAGR of 2.4% during the forecast Period (2026-2035). The US FDA's reliance on approved antiviral therapies for Influenza A and B ensures consistent access to treatments, promoting market stability and encouraging global healthcare provider adoption, which supports market growth. For instance, in March 2026, the US Food and Drug Administration (FDA) continues to rely on its existing antiviral approvals for the treatment of influenza virus infections, which include medications active against both Influenza?A and B viruses, such as oseltamivir, zanamivir, peramivir, and baloxavir marboxil (marketed as Xofluza). These antivirals are approved to treat acute uncomplicated influenza and, in some cases, are also indicated for post?exposure prophylaxis of influenza infections across age?appropriate groups when initiated early after symptom onset. Baloxavir’s approved indications were expanded over time to include treatment and prevention in pediatric populations aged?5?years and older, reflecting evolving use recommendations within the FDA framework.

Browse the full report description of “Influenza Virus B Infection Drug Market Size, Share & Trends Analysis by Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Others), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/influenza-virus-b-infection-drug-market

FDA Accepts IND Submission for Novel Influenza B Antiviral Therapy

• In January?2026, Traws?Pharma filed an Investigational New Drug (IND) application with the US FDA for tivoxavir marboxil (TXM), a potential novel oral endonuclease?inhibitor antiviral intended for the treatment of influenza (including type?B). This submission marks a pipeline advancement toward a new influenza therapeutic that could diversify treatment options beyond currently approved drugs like baloxavir (Xofluza) and neuraminidase inhibitors.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AstraZeneca, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), Sanofi, Shionogi & Co., Ltd., among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Influenza Virus B Infection Drug Market Report Segment

By Therapeutic Type

• Dermatology
• Obesity
• Sexual Dysfunction
• Insomnia
• Depression / Anti-depressants
• Smoking Cessation
• Women’s Health / Contraceptives
• Others

By Drug Form

• Tablets
• Gels
• Oral Syrups
• Parenteral (Injectables)
• Creams
• Chewing Gums
• Others

By End-User

• Hospital-based Distribution
• Retail Pharmacies / Drug Stores
• Online Pharmacies / E-commerce Platforms
• Clinics & Specialty Centers
• Others

Global Influenza Virus B Infection Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/influenza-virus-b-infection-drug-market